Mirvetuximab soravtansine (MIRV), an ADC targeting folate receptor alpha (FRα), is now recognized as a standard of care treatment in platinum-resistant ovarian cancer, following the results of the phase III MIRASOL trial, which demonstrated improved response rates and survival outcomes compared to single agent chemotherapy [18, 19]. Here, FOLR1 is linked to ovarian carcinoma.